Table 2.
Study outcomes
| Outcomes |
TXA |
Placebo |
RD |
RR |
|---|---|---|---|---|
| (n = 120) | (n = 118) | [95% CI] | [95% CI] | |
| Progressive intracranial haemorrhage (PIH) |
21 (18%) |
32 (27%) |
−0.10 |
0.65 |
| moderate TBI (n = 24) |
7 (6%) |
17 (14%) |
[(−0.20)- |
[0.40-1.05] |
| severe TBI (n = 20) |
9 (8%) |
11 (9%) |
(−0.01)] |
|
| indicated neurosurgery |
6 (5%) |
6 (5%) |
|
|
| Increase in pressure effect* |
*11 (10%) |
12 (11%) |
−0.01 |
0.91 |
| [(−0.09) – 0.07] |
[0.42-1.97] |
|||
| Improved GCS motor score at 24 hours |
37 (31%) |
37 (31%) |
−0.01 |
0.98 |
| [(−0.12) – 0.11] |
[0.67-1.44] |
|||
| Neurosurgical intervention |
3 (3%) |
0 |
0.03 |
--- |
| [(−0.00) – 0.05] |
--- |
|||
| Blood products transfusion |
31 (26%) |
33 (28%) |
−0.02 |
0.92 |
| [(−0.13) – 0.09] |
[0.61-1.40] |
|||
| Death |
12 (10%) |
17 (14%) |
−0.04 |
0.69 |
| [(−0.13) – 0.04] |
[0.35-1.39] |
|||
| Unfavorable (GOS) outcome |
21 (18%) |
27 (23%) |
−0.05 |
0.76 |
| [(−0.16) – 0.05] |
[0.46-1.27] |
|||
|
Adverse events |
|
|
||
| Stroke |
0 |
3 |
--- |
--- |
| Pulmonary embolus |
0 |
0 |
--- |
--- |
| Deep vein thrombosis |
0 |
0 |
--- |
--- |
| Gastrointestinal bleeding | 0 | 1 | --- | --- |
*Denominator for outcomes is 114 for TXA group and 115 for placebo group. This is an analysis based on complete case analysis that is not assumed the missing outcome.